Pipeline · Bill → Law
Step 1
Introduced
Mar 30, 2023
Step 2
Referred
Mar 30, 2023
HELP
Step 3
Committee
Step 4
Senate
Step 5
House floor
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary
This bill authorizes an applicant seeking Food and Drug Administration (FDA) approval for a generic drug (or biosimilar product) to sue to correct or delete patent information provided by the maker of the reference drug (or reference biological product). Typically, a generic drug is a lower-cost version of a reference drug that gets introduced after the patents covering a reference drug have expired. When the maker of the reference drug first applies for FDA approval to sell the drug, the maker must provide various information to the FDA about the patents that it believes cover the drug, including in the form of use codes that describe any methods of using the drug that the reference drug m...
Timeline · 2 actions
Mar 30, 2023
Introduced in Senate
Mar 30, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.